- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01892215
Blood Loss During Cesarean Section. Comparing Two Techniques of Blunt Expansion of Uterine Incision: Transversal vs. Cephalad-caudad,
June 20, 2017 updated by: Osvaldo A. Reyes T., Saint Thomas Hospital, Panama
Blood Loss During Cesarean Section. Comparing Two Techniques of Blunt Expansion of Uterine Incision: Transversal vs. Cephalad-caudad. A Randomized, Controlled Trial.
Obstetrical blood loss is an important reason of maternal morbidity and mortality.
Because of the increase in the rate of cesarean section, any procedure that could help reduce blood loss during cesarean section should be investigated.
The purpose of this study was to compare 2 methods of blunt expansion of the uterine incision at the time of cesarean delivery: transversal vs. cephalad-caudad.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
839
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Panama, Panama
- Saint Thomas Maternity Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Singleton pregnancies
- Gestational age: 34 weeks or more
- Delivery by cesarean section
- Presurgical hemoglobin > 10.5 g/dL
Exclusion Criteria:
- Two or more previous cesarean sections
- History of uterine rupture in a previous pregnancy
- History of myomectomy
- History of abdominal trauma with an uterine lesion
- Blood dyscrasia
- Multiple pregnancy
- Placenta previa
- Abruptio placenta
- Stillbirth
- Sharp uterine expansion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cephalad-caudad
Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
|
Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
|
|
Experimental: Transversal expansion
Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
|
Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood loss (hemoglobin level)
Time Frame: 72 hours
|
Difference in hemoglobin level between 24 hours pre-surgery and the hemoglobin level before leaving the hospital.
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Surgical complications
Time Frame: 72 hours
|
Number of cases of surgical complications (hematomas, unintended extension of the uterine incision, need for transfusion) between the two techniques.
|
72 hours
|
|
Unintented extension of uterine incision
Time Frame: 72 hours
|
Number of cases of unintended extension of the uterine incision during surgery between the two techniques.
|
72 hours
|
|
Hematoma formation
Time Frame: 72 hours
|
Number of cases of hematoma formation during or after between the two techniques.
|
72 hours
|
|
Need for transfusion
Time Frame: 72 hours
|
Number of cases that required a blood transfusion between the two techniques.
|
72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Osvaldo Reyes, MD, Saint Thomas Maternity Hospital
- Principal Investigator: Alberto Morales, MD, Saint Thomas Maternity Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Actual)
May 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
June 30, 2013
First Submitted That Met QC Criteria
June 30, 2013
First Posted (Estimate)
July 4, 2013
Study Record Updates
Last Update Posted (Actual)
June 22, 2017
Last Update Submitted That Met QC Criteria
June 20, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MHST2012-08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blunt Expansion of the Uterine Incision
-
Istanbul Bakirkoy Maternity and Children Diseases...CompletedDisruption of Uterine Incision After Cesarean SectionTurkey
-
Duke UniversityWallace H. Coulter FoundationCompletedCancer of the Cervix, Cancer of the EndometriumUnited States
-
Government Medical College, PatialaCompletedInexpensive Closure of Fasciotomy Incisions Without the Need for Skin Grafting
-
Mansoura UniversityUnknownProstate Hyperplasia | Transurethral Incision Of The Prostate | Ejaculatory DysfunctionEgypt
-
Kaplan Medical CenterHillel Yaffe Medical Center; Barzilai Medical CenterRecruitingRadiation Therapy | Cancer of the Cervix | Conization of the CervixIsrael
-
Eli Lilly and CompanyCompletedCancer of CervixMexico, Thailand, Argentina, Bosnia and Herzegovina, India, Pakistan, Peru
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruitingTo Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
-
University Hospital, GenevaCompletedCancer of the Uterine Cervix
-
Women's Hospital School Of Medicine Zhejiang UniversityAkesoNot yet recruitingCervical Cancer | Uterine Cervical Neoplasms | Cancer of Cervix | Uterine Cervical Cancer | Cervical Neoplasms | Cancer of the Uterine Cervix
-
Tata Memorial HospitalCompletedCervical Cancer | Cervix Cancer | Cancer of Cervix | Cancer of the CervixIndia
Clinical Trials on Cephalad-caudad expansion
-
North East London Foundation TrustUnknownDepression | Personality DisorderUnited Kingdom
-
Restorbio Inc.WithdrawnClinically Symptomatic Respiratory Illness
-
Shanghai Jiao Tong University School of MedicineCompletedTissue Expander DisorderChina
-
Universidade Federal de GoiasUnknown
-
Pontifícia Universidade Católica de Minas GeraisCompletedCleft Lip and Palate | Nasal Septum; Deviation, Congenital | Maxillary Hypoplasia
-
Fundación Universitaria CIEOUnknownMaxillary AnomalyColombia
-
Al-Azhar UniversityCompletedKnife Edge Alveolar RidgeEgypt
-
Erasme University HospitalRecruitingNarrow MaxillaBelgium
-
Cairo UniversityCompleted
-
University of GenovaUniversity of Milan; Università degli Studi di BresciaNot yet recruitingMaxillary Deficiency